reports
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon ...
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson’s disease Additional data from the trial will be presented at a future medical mee...
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinso...
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET. Cerevel will lead an in-depth discussion of tavap...
Cerevel Therapeutics to Present at Upcoming Investor Conferences
Cerevel Therapeutics to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the management team will participate in two upcoming investor conferences during the month of November. President and chief executive officer Ron Renaud will also participate in fireside chats at both conferences. Event:Jefferies London Healthcare Conference Date:November 14, 2023Time: 9:00 a.m. GMT fireside chat Event:6th Annual Eve...
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and ...
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results fo...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
CEM CLEARBRIDGE ENERGY MLP FUND INC.
RMAX RE/MAX HOLDINGS INC.
OXBR OXBRIDGE RE HOLDINGS
NTRS NORTHERN TRUST CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
DG DOLLAR GENERAL CORPORATION
CTRN CITI TRENDS INC.
COTY COTY INC. CLASS A
BLFS BIOLIFE SOLUTIONS INC
ALDX ALDEYRA THERAPEUTICS
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
SHW SHERWIN-WILLIAMS COMPANY
QRHC QUEST RESOURCE HOLDING
ADC AGREE REALTY CORPORATION
CCL CARNIVAL CORPORATION
POH3 CARNIVAL PLC
PAGP PLAINS GP HOLDINGS LP CLASS A
AGX ARGAN INC.
PTGX PROTAGONIST THERAPEUTICS
ASTI ASCENT SOLAR TECHNOLOGIES
MHI INC.
AXR PIONEER MUNICIPAL HIGH INCOME TRUST
BCEL AMREP
SCU ATRECA
RMBI SCULPTOR CAPITAL MANAGEMENT INC (A)
CAPR RICHMOND MUTUAL BANCORPORATION
GLT INC.
CERE CAPRICOR THERAPEUTICS
AVO GLATFELTER CORPORATION
PUBM CEREVEL THERAPEUTICS HOLDINGS (A)
IMNM MISSION PRODUCE
GNSS PUBMATIC
RBLX IMMUNOME
CYTH GENASYS INC
SMMT ROBLOX
ME CYCLO THERAPEUTICS
ATXS SUMMIT THERAPEUTICS INC
ERAS 23ANDME HOLDING CO.
GAIA ASTRIA THERAPEUTICS INC
EMO ERASCA INC
BHVN GAIA GROW CORP
BANX CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
BIOHAVEN LTD
STONECASTLE FINANCIAL CORP.
- Jonathan Moreland
CTRN CITI TRENDS INC.
ALDX ALDEYRA THERAPEUTICS
BRN BARNWELL INDUSTRIES
FNKO FUNKO CLASS A
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
SRRK SCHOLAR ROCK HOLDING CORPORATION
DOCU DOCUSIGN INC.
DCTH DELCATH SYSTEMS
CERE CEREVEL THERAPEUTICS HOLDINGS (A)
AVO MISSION PRODUCE
PUBM PUBMATIC
SODI SOLITRON DEVICES INC.
NRGX PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
RBLX ROBLOX
SMMT SUMMIT THERAPEUTICS INC
ME 23ANDME HOLDING CO.
ATXS ASTRIA THERAPEUTICS INC
SNCY SUN COUNTRY AIRLINES HLDGS INC
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
EMO CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
TTOO T2 BIOSYSTEMS INC.
- Jonathan Moreland
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
SRRK SCHOLAR ROCK HOLDING CORPORATION
CERE CEREVEL THERAPEUTICS HOLDINGS (A)
NRGX PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
ATXS ASTRIA THERAPEUTICS INC
SNCY SUN COUNTRY AIRLINES HLDGS INC
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
EMO CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results an...
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023 CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To a...
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering...
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 shares of its common stock at a public offering price of $22.81 per share, or approximately $450 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to purchase up...
Cerevel Therapeutics Announces Proposed Public Offering of Common Stoc...
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $400.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less unde...
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global H...
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023. President and chief executive officer Ron Renaud will participate in a fireside chat at 9:30 AM ET. The live webcast of the fireside chat can be accessed on the investor relations ...
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and...
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- , (Nasdaq: CERE), a company dedicated to unraveling the mys...
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results a...
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023 CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wednesday, August 2, 2023, before the U.S. financial markets open. Management will host a conference call to discuss second quarter financial results and business updates on Wednesday, August 2 at 8:00 a.m. ET. To access...
Cerevel Therapeutics Holdings Inc: 1 director
A director at Cerevel Therapeutics Holdings Inc sold/sold after exercising options 200,000 shares at 34.430USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the co...
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Developme...
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer Mr. Burgess will be responsible for leading Cerevel’s business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. “I am so pleased to welcome Paul to Cereve...
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financ...
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. ...
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Execut...
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two prior CEO roles and strong financial and operational experience Emraclidine Phase 2 schizophrenia data readout on track for 1H 2024 Darigabat Phase 2 epilepsy data readout expected mid-year 2024; panic disorder Phase 2 trial expected to initiate i...
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Car...
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA Securities Health Care Conference. Date: Wednesday, May 10th Format: Presentation at 10:00 am PT (1:00 pm ET) The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics web...
Cerevel Therapeutics to Report First Quarter 2023 Financial Results an...
Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023 CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2023 financial results and business updates on Wednesday, May 3, 2023, before the U.S. financial markets open. Management will host a conference call to discuss first quarter financial results and business updates on Wednesday, May 3 at 8:00 a.m. ET. To access the call, ...
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will participate in a fireside chat at the Stifel Virtual 2023 CNS Days on Wednesday, March 29, 2023 at 10:30 am ET. The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website . A replay will be available in the same section of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.